|
EMV Capital PLC - life sciences-focused investor - Reports results for 2025. Assets under management totals £112.5 million as at December 31, up from £98.5 million one year prior. Group revenue increases 17% to £2.9 million from £2.5 million the year before, ‘driven by higher corporate finance fees, increased fundraising activity and higher recurring fund management fees following the full operational integration of Martlet Capital.’ Core revenue increases 31% to £3.2 million from £2.4 million. Pretax loss narrows to £685,000 from £3.7 million. EMV says syndicated fundraising during the period totalled £12.0 million across 14 portfolio companies, up from £10.6 million across 12 companies. Looking ahead, Chief Executive Officer Ilian Iliev comments: ‘The accelerating demands of AI infrastructure, energy efficiency, healthcare innovation and industrial resilience continue to reinforce the relevance of our portfolio. Several portfolio companies are approaching important commercial, technical and regulatory milestones, and we believe the group is well positioned to benefit as market conditions improve. While we remain disciplined and cautious, we are increasingly optimistic about the medium-term opportunity set across both our existing portfolio and new investment pipeline.’ Current stock price: 46.00 pence, down 4.2% in London on Tuesday 12-month change: up 14% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
